The device has been usesd in more than 15,000 cases globally, according to a news release. It features a wide range of implants for interbody fusion.
Implanet’s CEO, Ludovic Lastennet, said SqualeTM is expected to launch in the U.S. by summer.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
